Latest News - Novartis

Wednesday, September 13, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Novartis

Five-Year Data Show Sustained Efficacy, Safety for Cosentyx

Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase …

Read the full story

Monday, March 06, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Novartis, Psoriasis

Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humira

Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. …

Read the full story

Thursday, July 14, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates, Novartis

FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandoz

The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five in…

Read the full story

Wednesday, June 29, 2016 | PracticalDermatology.com, Research and Publications, National Psoriasis Foundation, Novartis

Global Psoriasis Survey: 85% of US Respondents Faced Social Stigma Because of Psoriasis

Novartis released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85 percent of US respondents have su…

Read the full story

Friday, March 18, 2016 | PracticalDermatology.com, Research and Publications, Amgen, Novartis

Study Links Psoriasis to Bone Loss. Is IL-17 to Blame?

Psoriasis is linked to widespread bone loss, according to Researchers from the Genes, Development and Disease Group at the Spanish National Cancer Research Centre (CNIO) in Madrid. The new study, w…

Read the full story

Friday, February 12, 2016 | Acquisitions and Mergers, PracticalDermatology.com, Product Launches and Updates, Johnson & Johnson, Novartis

Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in US

Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights …

Read the full story

Thursday, January 28, 2016 | Healthcare Trends, Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Novartis

Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Education

Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the differen…

Read the full story

Wednesday, January 20, 2016 | PracticalDermatology.com, Novartis

FDA Approves Two New indications for Cosentyx

The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). …

Read the full story

Monday, November 23, 2015 | FDA Approval/Clearance, PracticalDermatology.com, Novartis

Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanoma

The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresect…

Read the full story

Thursday, October 01, 2015 | Phase 3/4 Trials, Research and Publications, Novartis

Secukinumab Phase III Data Confirm Significant Efficacy in Patients with Psoriatic Arthritis

Results from the Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in The New England Journal of Medicine (NEJM). Secukinumab is the first inte…

Read the full story

Monday, August 24, 2015 | Product Launches and Updates, Novartis

Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinoma

Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBC…

Read the full story

Friday, July 24, 2015 | FDA Approval/Clearance, PracticalDermatology.com, Novartis

FDA Approves Odomzo for Locally Advanced BCC

The FDA approved Novartis’ Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred follo…

Read the full story

Friday, July 24, 2015 | FDA Approval/Clearance, Phase 3/4 Trials, PracticalDermatology.com, Novartis

Novartis Combination Therapy Tafinlar and Mekinist Receives FDA Priority Review Designation

The FDA has granted priority review for the same patient population for the combination of Novartis’ Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients…

Read the full story

Wednesday, January 21, 2015 | FDA Approval/Clearance, PracticalDermatology.com, Novartis

FDA Approves First IL-17A antagonist Cosentyx (secukinumab) from Novartis for Moderate to Severe Plaque Psoriasis

The FDA approved Cosentyx™ (secukinumab) from Novartis for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosenty…

Read the full story